Phoenix Financial Ltd. Purchases 20 Shares of IDEXX Laboratories, Inc. $IDXX

Phoenix Financial Ltd. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,181 shares of the company’s stock after purchasing an additional 20 shares during the period. Phoenix Financial Ltd.’s holdings in IDEXX Laboratories were worth $633,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of IDXX. GAMMA Investing LLC increased its stake in IDEXX Laboratories by 42.7% in the first quarter. GAMMA Investing LLC now owns 2,187 shares of the company’s stock valued at $918,000 after purchasing an additional 654 shares in the last quarter. Asset Management One Co. Ltd. increased its stake in IDEXX Laboratories by 5.7% in the first quarter. Asset Management One Co. Ltd. now owns 55,872 shares of the company’s stock valued at $23,463,000 after purchasing an additional 3,028 shares in the last quarter. Legacy Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 2.5% in the first quarter. Legacy Advisors LLC now owns 1,975 shares of the company’s stock valued at $829,000 after buying an additional 48 shares during the period. Sheets Smith Wealth Management acquired a new position in shares of IDEXX Laboratories in the first quarter valued at approximately $244,000. Finally, Bessemer Group Inc. boosted its holdings in shares of IDEXX Laboratories by 48.3% in the first quarter. Bessemer Group Inc. now owns 340,062 shares of the company’s stock valued at $142,810,000 after buying an additional 110,816 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. BTIG Research upped their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Piper Sandler reiterated a “neutral” rating and issued a $700.00 price target (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Morgan Stanley upped their price target on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a report on Friday, August 15th. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a “buy” rating and a $625.00 price target for the company. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $656.50.

IDEXX Laboratories Trading Down 0.5%

Shares of NASDAQ:IDXX opened at $633.78 on Thursday. The company’s 50-day moving average price is $638.91 and its two-hundred day moving average price is $554.07. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12. The stock has a market capitalization of $50.70 billion, a PE ratio of 52.77, a price-to-earnings-growth ratio of 4.12 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the previous year, the firm posted $2.44 EPS. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 8,411 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the sale, the executive vice president owned 7,132 shares in the company, valued at $4,477,041.68. This trade represents a 54.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael G. Erickson sold 406 shares of the stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the completion of the sale, the executive vice president owned 11,287 shares of the company’s stock, valued at approximately $7,336,098.52. This represents a 3.47% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.